Roxanne Marshall

TL;DR: The five glioma molecular groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis.

TL;DR: Findings support the role of c-Met in survival in hypoxia and invasion, features associated with antiangiogenic therapy resistance, and growth and therapeutic resistance of xenografts resistant to antiangIogenic therapy.

TL;DR: Molecular classification of astrocytomas by IDH mutation, TP53 mutation, and /or ATRX loss of expression revealed that CDKN2A loss in IDH/TP53 mutated tumors was strongly associated with worse overall survival, and testing may provide further clinical aid in lower-grade glioma substratification beyond 1p19q codeletion status.

TL;DR: It is demonstrated that in a subset of initially IDH 1 mutant gliomas IDH1 is deleted or amplified at recurrence, yielding a higher grade tumor with a reprogrammed epigenome, further suggestive of selection against the heterozygous mutant state as tumors progress.

TL;DR: The data show that the ALT and ATRX protein alterations are common in both pediatric and adult high-grade astrocytomas, often with associated PDGFRA gene amplification.